Another approval for new Fabry disease medicine Elfabrio

Privately-held drugmaker Chiesi has secured approval from the British medicines regulator for Elfabrio (pegunigalsidase alfa) in Fabry disease (FD).

The Italian firm has developed Elfabrio as a long-term enzyme replacement therapy for adults with FD, a serious lysosomal storage disorder which can result in impaired peripheral sensation and organ failure.

Chiesi is working with Israel’s Protalix BioTherapeutics (TASE: PLX) in the development of the therapy, the first and only enzyme replacement therapy of its type in this indication.